Central Hospital, Nancy, France
RENAUD Mathilde
Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction. This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.
Alzheimer Disease
skin biopsy
Not Applicable
| Study Type : | Interventional |
| Estimated Enrollment : | 30 participants |
| Masking : | None (Open Label) |
| Primary Purpose : | Other |
| Official Title : | Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease |
| Actual Study Start Date : | February 2024 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | December 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: alzheimer's disease patients Alzheimer's disease patients with positive biomarkers who started their disease before age 75 and benefited from genetic research. |
Other: skin biopsy |
|
Other: Control group control cell lines from patients free of alzheimer's disease |
Other: skin biopsy |
| Ages Eligible for Study: | |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Nancy Regional University Hospital Center
Nancy, France, 54000